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ABSTRACT v-abl, the oncogene transduced by Abelson
murine leukemia virus, was frst characterized by its ability to
transform lymphoid cells. bcr-abl, the oncogene formed by a
t(9;22) trauslocation thought to occur in human hematopoietic
stem cells, is detectable in almost all cases of chronic myelog-
enous leukemia (CML), a malignancy of granulocytic cells.
bcr-abl also causes a CML-like syndrome in mice whose
bone-marrow cells are infected with a retrovirus transducing
the gene. More recent reports have suggested that v-abl can,
however, cause a disease similar to CML. We demonstrate here
that v-abl, when transduced in a helper virus-containing sys-
tem, causes disease similar to, but distinct from, the CML-ilke
syndrome induced by ber-abl. Animals whose bone marrow has
been infected by v-abl virus develop modest splenomegaly,
marked granulocytosis, and malignant disease of several he-
matopoietic cell types. Unlike animals with CML-like disease
resulting from bcr-abl, the polymorphonuclear leukocytes
from animals infected with a v-abl construct do not contain the
v-abl provirus at a significant frequency. Histopathologic anal-
ysis also shows significant differences between the diseases
caused by v-abl and bcr-abl.
Activated variants of the c-abl protooncogene code for
proteins that transform a wide range ofhematopoietic cells as
well as other cell types. v-abl, the gene transduced by
Abelson murine leukemia virus (A-MuLV), originated in a
lymphoid tumor (1). The v-abl gene product is a 160-kDa
tyrosine kinase (p160) whose N-terminal domain consists of
MuLV core protein (gag) sequences; its 1003 C-terminal
amino acids are homologous to c-abl (2). Under commonly
used infection conditions, v-abl readily transforms B-lym-
phoid cells. The disease caused by intraperitoneal injection of
susceptible newborn mice is characterized by a short latent
period (1-3 mo), paraspinous masses of lymphoid cells, and
a distinctive cranial involvement ("caput medusa"). v-abl
can also transform fibroblasts, pre-B cells, T cells, mast cells,
macrophages, and erythroid cells, but these lineages are not
commonly involved in vivo (3). More recently, Kelliher et al.
(4) and Chung et al. (5) have suggested that v-abl can cause
a disease reminiscent of chronic myelogenous leukemia
(CML).
In humans, the t(9;22) translocation giving rise to the
Philadelphia chromosome appends 5' exons from an unre-
lated cellular gene, bcr, to the second exon of c-abl and gives
rise to a fusion gene, bcr-abl. Production of the correspond-
ing chimeric abl protein (p210 or p190) results in the leuke-
mias of mature granulocytes (CML) or lymphoid series cells
(Philadelphia chromosome-positive acute lymphocytic leu-
kemia, ALL) (for review, see ref. 6). Several studies have
attempted to recapitulate CML-like disease in a murine
model system by retroviral transduction of the bcr-abl gene
(4, 7, 8). The malignancies induced by these protocols have
varied somewhat, but a wide range of hematopoietic cell
types are typically involved. Central features ofthe CML-like
syndrome observed by Daley et al. (8) included massive
splenic enlargement secondary to infiltration with mature
granulocytes, a marked peripheral blood leukocytosis, and
the presence of a bcr-abl provirus in the granulocytes of
diseased animals. This syndrome is different from the ma-
lignancies of monocytic cells described by Kelliher et al. (4);
these most closely resemble human histiocytic lymphomas
not typically associated with the Philadelphia chromosome.
More distinct still are the tumors of macrophage and eryth-
roid derivation characterized by Elefanty et al. (7).
To compare the abilities of v-abl and bcr-abl to cause
CML-like disease, we placed the gene in the vector described
by Daley et al. (8), created a virus stock of high titer through
use ofhelper virus, and employed the same infection protocol
as in the previous study. We show here that v-abl induces a
range of malignancies similar, but not identical, to those
caused by bcr-abl.
MATERIALS AND METHODS
Viral Stocks and Infections. A 4.7-kilobase (kb) BamHI
fragment containing the v-abl sequence coding for p160
protein was subcloned into the pGD vector. The 5' long
terminal repeat of this vector is derived from Moloney
MuLV; the 3' long terminal repeat is a composite of the
myeloproliferative sarcoma virus promoter and MuLV en-
hancer (8). The B2 mutation (9) and internally promoted neo
markers are as described (8). The construct was cotrans-
fected with pZAP [a M-MuLV clone; (10)] into NIH 3T3
cells, and a transformed producer cell population was iso-
lated. Titers for both transformation (as assayed by focus
formation on NIH 3T3 cells) and neo resistance from viral
supernatants were >106 per ml.
Bone-Marrow Infections. Male BALB/c donor mice (8-12
weeks of age) were injected with 5-fluorouracil (5 mg each or
=e200 mg/kg) and sacrificed 6 days later. Marrow cells from
tibia and femur were pooled, washed once with phosphate-
buffered saline, and layered onto a cushion of Ficoll-Paque
(Pharmacia) at a maximum of 107 nucleated marrow cells per
ml of Ficoll solution. After centrifugation at 1500 x g for 30
min, the mononuclear cells at the Ficoll-phosphate-buffered
saline interface were washed twice in phosphate-buffered
saline. Nearly confluent virus-producing NIH 3T3 cells in
100-mm plates were killed by y irradiation (5000 R; 1 R =
0.258 mC/kg); each plate was then overlaid with 2-5 x 106
mononuclear marrow cells in 10 ml of Dulbecco's modified
Eagle's medium/10% calf serum/20% WEHI-3B-condi-
tioned medium/Polybrene at 0.4 ,ug/ml. After 60-72 hr co-
Abbreviations: CML, chronic myelogenous leukemia; JH, heavy-
chain joining region; A-MuLV and Mo-MuLV, Abelson and Molo-
ney murine leukemia virus, respectively. MPSV, myeloproliferative
sarcoma virus.
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cultivations, nonadherent marrow cells were harvested by
gently squirting the monolayer several times. Nonadherent
cells thus obtained were washed once in phosphate-buffered
saline and injected into lethally irradiated (two doses of 450
R y irradiation, separated by 3-6 hr) female recipients at
1.0-2.5 x 105 cells per animal.
Establishment of Cell Lines. Cells from the resulting tumor
masses and bone marrow of each animal were seeded in
RPMI medium/20% fetal calf serum/penicillin/streptomy-
cin/50 tiM 2-mercaptoethanol at 2-5 x 106 cells per ml. After
4-8 days, medium was replaced, and nonadherent cells were
passed 1:2 into fresh medium. The procedure was repeated
until nonadherent cells became capable of growth with a
doubling time of 24-48 hr.
Examination of Diseased Animals. Animals from three
separate transplants (total 22 animals) were included in this
study. Total and differential white blood cell counts were
obtained by retroorbital bleeding of anesthestized mice at
2-week intervals beginning -4 weeks after transplant. One
hundred percent of animals reconstituted with infected mar-
row developed disease. Those animals for which data is not
shown died within 16 weeks of transplant but were too long
dead to allow complete autopsy and analysis. For the re-
mainder, 0.5-1.0 ml of peripheral blood was obtained at
sacrifice and fractionated on Ficoll/Paque gradients as
above. Cells pelleting through the gradient were >95% poly-
morphonuclear granulocytes, as assayed by Wright-Giemsa
staining. Permanent (formalin fixed) sections were made
from liver, spleen, thymus, lymph node, and any visualized
tumor mass. Cells from spleen or tumor masses were cultured
as described; seven cell lines from different animals were
obtained.
Hybridization and Protein Studies. DNA was prepared from
peripheral blood granulocytes, liver, spleen, nodes, and
tumor masses per standard protocols. After digestion with
specified enzymes, DNAs were blotted to nylon membranes.
Cytoplasmic RNAs were also obtained from cell lines, elec-
trophoresed, and blotted by standard techniques onto sup-
ported nitrocellulose filters (11). Gel-purified fragments used
as probes included the 1.2-kb G418-resistance cassette (Cia
I digest) from the pGD vector, a 2.5-kb c-abl-specific frag-
ment (HincIl digest) from pRS-2 (12), and a 2-kb mouse
/3-globin (HindIII-BamHI) fragment excised from plasmid
pUCMImaj, which contains the mouse /8-globin major locus
described by Konkel et al. (13) and was provided by M.
Baron (Harvard University). Also used was a mixture of Zfx-
and Zfy-specific DNA fragments [(pDP1055 and pDP1193,
provided by E. M. Simpson and D. C. Page (Whitehead
Institute); (14)] to determine the sex of origin of tumor cell
lines. A probe containing the coding region of the murine
erythropoietin receptor (15) was supplied by G. Longmore,
Whitehead Institute. Probes to chicken 8-actin and Rag-],
one of the genes central to variable-diversity joining region
recombination in pre-B cells (16), were obtained from D.
Schatz (Whitehead Institute). A 3.4-kb BamHI-EcoRI ge-
nomic clone, pJH1-4, encompassing J14 of the immunoglob-
ulin kL locus was provided by M. Schlissel (Whitehead
Institute).
RESULTS
Histopathology. Twenty-two lethally irradiated animals
were injected with bone marrow infected by v-abl-containing
virus. All animals were deemed reconstituted insofar as they
survived longer than 2 weeks after irradiation, but all died
within 16 weeks of transplant. Data is shown for those mice
sacrificed when moribund; the remainder were not well
enough preserved to allow complete autopsy. Each recipient
mouse examined had developed disease of multiple hemato-
poietic lineages.
Table 1 shows the results of peripheral blood studies and the
disease histology ascertained by hematoxylin/eosin sections in
individual animals. The disease latency of 4-10 weeks is com-
parable to that reported in previous studies using v-abl in a
similar protocol (4) and to that observed for the bcr-abl-
associated CML-like disease reported by Daley et al. (8). The
mice carrying cells infected with v-abl under these conditions
developed an abnormal peripheral blood granulocytosis sug-
gestive of, but not by itselfdiagnostic of, a CML-like syndrome.
Beyond these similarities, significant differences between the
diseases caused by v-abl and bcr-abl were evident. (i) The
average white blood cell counts in our v-abl mice were substan-
tially lower than in those mice that received bcr-abl virus by a
similar protocol: the maximum of 61,000 reported here is nearly
an order ofmagnitude lower than the maximum recorded in mice
receiving marrow infected by bcr-abl and is comparable to the
number reported by Kelliher et al. (4) in similar studies. (it) The
granulocytes of v-abl-infected mice were almost entirely mature
cells, whereas animals with a true CML-like syndrome exhibited
both mature and immature cells in their peripheral blood. (iii) The
marked splenomegaly occurring in mice that have received
p210-expressing marrow was not present in the v-abl-infected
mice. Mean spleen weights of0.60 ± 0.17 g noted in our previous
study of bcr-abl-infected mice are significantly greater than the
0.30 ± 0.03 g observed here; spleen weights for untreated
BALB/c mice of this age are =0.1 g. (iv) Hematoxylin/eosin
staining of spleen sections from v-abl-infected animals revealed
splenic disease very different from that occurring in bcr-abl-
Table 1. Histopathology of v-abl-infected mice
Latency*, WBC, x Differentialt Organ involvements
Mouse weeks 1O-3/pl P L M Spleen weight, g SpI Liv LN EN
4/7 CN 10 36.5 90 5 4 0.15 L, M M + PS
6/8 AN 6 24 64 10 16 0.28 L, M L, M - T
6/8 AL-2 6 41 58 34 8 0.33 L, E M, E - PS, T
6/20 AN 5 35 50 45 5 0.37 L, M, E L, M + T
6/20 AR-2 4 58 68 20 12 0.35 L L, E + PS, T
6/20 AL-1 4 25.5 47 45 8 0.28 L, M, E L, M + -
6/20 BN 4 37 55 32 13 0.28 L, M, E M + PS, T
6/20 CR-1 5 52 54 36 10 NA L, M L, M + T
6/20 CR-2 5 61 55 35 10 0.30 L, M L - -
6/20 CL-1 5 39 69 17 14 0.37 L, E L + PS, T
WBC, white blood cells; NA, not available.
*Time elapsed from transplant of v-abl-infected bone marrow to death of the animal.
tDifferential WBC counts: P, polymorphonuclear granulocyte; L, lymphocyte; M, monocyte; no significant basophilia or eosinophilia were
noted.
tSpl, spleen; Liv, liver; LN, lymph node; EN, extranodal; L, lymphoid; M, monocytoid; E, erythroid; PS, paraspinous mass present; T, thymus
involved.
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FIG. 1. Histochemical staining of tissues from a representative mouse (4/7 CN). (a) Wright-Giemsa stain of peripheral blood, demonstrating
numerous polymorphonuclear cells. (b) Hematoxylin/eosin staining oflymph node (x 85) showing effacement of usual architecture and capsular
invasion. (c) Higher magnification (x350) of lymph node, showing lymphoblasts. (d) Cross section of paraspinous tumor mass, in which muscle
bundles are invaded by lymphoma cells. (e) Hematoxylin/eosin staining of spleen (x85) demonstrates macrophage, erythroid, and lymphoid
cells with minimal involvement by polymorphonuclear cells. (f) Nodule of macrophage-like cells with cells from other hematopoietic lineages
present at higher magnification (x350) of spleen. (g) Hematoxylin/eosin staining of liver tissue; normal hepatocytes surround a nodule of
macrophage-like cells. (h) Nodule of macrophage-like cells at higher magnification (x350) of liver tissue.
infected mice. In contrast to the complete obliteration of splenic
architecture by sheets of mature granulocytes in p210/CML
mice, spleens from v-abl-infected mice showed cells from several
major lineages (erythroid, lymphoid, and macrophage) but ex-
hibited minimal numbers ofmature granulocytes. The patterns of
disease also differed at other sites. Similar to previous reports, we
found that -50%o ofautopsied animals bore paraspinous masses
of lymphoma cells characteristic of more classical A-MuLV
disease. In addition, the occurrence oflymphoid disease at other
sites was nearly universal in mice receiving v-abl-infected mar-
row (Fig. 1, Table 1) but rare in mice receiving bcr-abl. The
extent and frequency of malignant lymphoid involvement was
such that it appeared to be the primary cause of death in nearly
all of these animals.
Localization of Provirus. A central feature ofthe previously
reported CML-like disease in mice was the presence of the
activated abl genome at near single-copy number in the
granulocytes of peripheral blood (8). Analysis ofDNA from
the Ficoll/Paque purified granulocyte population of v-abl
mice revealed that the viral genome was undetectable in these
cells. Hybridization of a neo probe to the Xba I-digested
DNAs from several mice failed to detect the gene in granu-
-+ + A B C D E F G H J K
FIG. 2. Xba I-digested primary granulocyte DNAs (2.5-5.0 l.g of
samples, lanes A-K) from Ficoll-pelleted cells from peripheral blood
of 11 primary animals. The DNAs have been hybridized with a
neo-specific probe. -, Digestion ofNIH 3T3 DNA; +, +, 2.5-Itg and5.0-I~g samples of DNA from a cell line (GR-1) known to contain a
single copy of the neo-resistance gene from pGD. Bar shows hy-
bridization to the predicted neo-containing fragment.
locytes (Fig. 2); hybridization with a c-ablprobe showed only
endogenous c-abl sequences (data not shown).
Cells from other tissues, however, contained v-abl at a
readily detectable copy number. A c-abl probe was hybrid-
ized to DNA from liver, spleen, and lymph node or tumor
tissue in representative mice. EcoRI cleaved the integrated
provirus in the neo cassette, yielding fragments the sizes of
which varied depending upon integration site. Xba I cuts
within the long terminal repeat sequences of the integrated
provirus, giving a fragment independent in length of the
integration site. In each case, primary lymphoid or macro-
phage tumor tissue contained a limited number (1-3) of
integrated proviruses detected either by neo or abl probes
(Fig. 3). These proviral genomes were present at significant
copy number (-0.5-1.0 copy per genome, as estimated from
the ratio of intensity of integrated provirus to endogenous
c-abl bands) in the liver, spleen, or tumor tissue of all animals
tested. These data established that v-abl was present in the
malignant cells in recipient animals.
Cell Lines. Tumor cells and bone marrow were harvested
from each autopsied animal and cultured. Cell lines were
established from seven independent tumors. These lines were
analyzed by Wright-Giemsa staining, antibody staining for
selected lineage markers, and Southern blotting to assay
provirus (c-abl and neo probes), immunoglobulin heavy-
chain gene configuration (JH probe), and origin (male donor
or female recipient). We also used Northern (RNA) blotting
to determine lineage and immunoprecipitation with anti-abl
sera to establish the presence ofp160 in the cell lines. Results
of these analyses are shown in Table 2.
Wright-Giemsa staining revealed different morphologies
among the cell lines, suggesting transformation of lymphoid
and macrophage lineages. Nonspecific esterase staining as
well as staining with monoclonal antibodies to pre-B cell
(B220), thymocyte (Thy 1.2), and macrophage (Mac-1) anti-
gens largely confirmed our initial impressions. Although the
majority of cultured cells were clearly of pre-B origin (B220'
and positive for immunoglobulin heavy-chain rearrangement
at both alleles), two Mac-i-positive cell lines and an appar-
ently lineage-negative line were obtained. The two Mac-1-
positive lines had, however, rearranged their g loci. They are
apparently similar to lines reported by Kelliher et al. (4) and
may represent a more primitive, multipotential population of
cells. The last line, although erythroid in appearance, did not
clearly stain with benzidine and failed to express mRNA
Proc. Natl. Acad. Sci. USA 88 (1991)
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FIG. 3. EcoRI-digested primary DNAs from representative tis-
sues of four mice, hybridized with a c-abl-specific probe. The major
band at 23 kb and the minor band at 7 kb represent endogenous c-abl
sequences, whereas other bands are virally transduced abl se-
quences. L, liver; S, spleen; T, tumor or node DNAs.
homologous to P3-globin, the erythropoietin receptor, or to
Rag-i [a gene central to variable/diversity/joining region
recombination in pre-B cells (16)]. However, these cells
exhibited JH rearrangements at both alleles (Fig. 4). In four
of five B220' lines, the mRNA for Rag-1 was readily de-
tected, and both JH alleles had undergone rearrangement,
similar to the pattern predicted from previously characterized
A-MuLV-transformed lines (17). All cells contained either
one or two copies of provirus detected by hybridization to
neo-specific probes, were of donor (male) origin by hybrid-
ization to Zfx/Zfy probes, and contained the characteristic
v-abl (p160) gene product, as assayed by immunoprecipita-
tion and autophosphorylation reactions (18).
DISCUSSION
On the basis of these and previous results, v-abl and bcr-abl
apparently differ in the spectrum of hematopoietic disease
they induce. The bcr-abl gene product likely initiates CML
in humans. A CML-like syndrome has been seen in nearly
half of the diseased mice transplanted in our laboratory with
bone-marrow cells that contain a retrovirally transduced
bcr-abl cDNA (8). This syndrome is characterized by mas-
sive splenic enlargement with total obliteration of splenic
architecture by mature granulocytes. These animals also
exhibit white blood cell counts similar to those in the human
disease. Notably, the provirus coding for p210 is present at
single-copy levels in these granulocytes.
v-abl causes a disease that differs by several criteria. (i)
Involvement of lymph node, spleen, or paraspinous tissues
by masses of lymphoblasts is nearly universal in animals
transplanted with v-abl-infected marrow. (it) Modest spleno-
megaly with much less extensive replacement of spleen cells
by abnormal granulocytes is present. (iii) Mice infected with
Table 2. Characteristics of cell lines derived from tumors or
bone marrow of v-abl-infected animals
Antigen mRNA DNA
Cell line B220* Mac-1* Thy-1.2 Globint RAG-1 At
4/7 CN + _ _ _ _ +/+
6/8AN - + - - - +/+
6/20 AN + - - - + +/+
6/20AR-2 +/- +1- - - + +/+
6/20 BN - - - - - +/+
6/20BL-1 + - - - + +/+
6/20 CL-1 + - - - + +/+
*+/- denotes a mixed population of cells, positive for either one
antigen or the other, as detected with simultaneous staining.
tResult was identical for erythropoietin-receptor mRNA.
t-, germ-line IgM configuration; +, rearrangement as assayed by
hybridization to a JH-region probe.
a v-abl-containing virus also exhibit a more modest granu-
locytosis in peripheral blood and do not harbor the provirus
at significant copy number in their granulocytes. In those
tissues where provirus is detectable, histology confirms that
the number ofgranulocytes is not sufficient to account for the
observed signal. Given these findings, we believe that the
granulocytes in these mice are not descended from the
malignant clone and are probably not malignant cells. A
potential explanation for this phenomenon is suggested by the
molecular analysis of Elefanty et al. (7), who found that a
number of their p210-transformed macrophage cell lines
produced biologically active granulocyte/macrophage colo-
ny-stimulating factor. Elaboration of a granulocyte-
stimulating factor by the frequently observed macrophage
nodules in our v-abl-infected mice might well account for the
peripheral blood picture described above.
Still, significant similarities in the diseases caused by v-abl
and bcr-abl are notable. As described in both our work above
and in previous studies by Kelliher et al. (4), mice infected
with marrow producing either gene product can develop
lymphoid and macrophage-like neoplasms. Cells from these
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FIG. 4. EcoRI-digested DNAs from indicated cell lines hybrid-
ized with probes detecting JH (J rearrangement). Lane designations
correspond to cell lines derived from the indicated mice or cell lines:
A, 4/7 CN; B, 6/8 AN; C, 6/20 AR-2; D, 6/20 BN; E, 6/20 BL-1;
F, 6/20 CL-1; G, GR-1, a B220+ pre-B cell line transformed by p210;
H, NIH 3T3 DNA (unrearranged). Numbers at left represent kb.
Medical Sciences: Scott et al.
6510 Medical Sciences: Scott et al.
masses readily give rise to cell lines that produce p160 and
that exhibit cell-surface markers characteristic of lymphoid
or myeloid lineages. Other early cells may be involved as
well, as evidenced by our isolation of one lineage-negative
cell line. The presence of nests of erythroid proliferation on
the histologic sections suggests, but does not prove, that
involvement of the erythroid lineage is possible in this
host/vector system using v-abl.
The phenotype of disease in animals infected by viruses
containing activated c-abl variants is determined by a number
of factors. One is the route of administration. Demonstration
of a pre-B cell tumor phenotype in animals receiving
A-MuLV i.v. or intraperitoneally was followed by the dem-
onstration that the virus could, after intrathymic injection,
transform T cells, even in mouse strains previously thought
resistant to Abelson virus transformation (19, 20). As we have
used identical infection protocols for bcr-abl and v-abl here,
other explanations for the difference in phenotype must be
sought. A second possibility is that infection of different
target-cell populations occurred. The lymphoid precursor
cell that A-MuLV transforms to yield pre-B cell tumors has
been relatively well characterized (21). Hematopoietic stem
cells are apparently involved in human disease (22), while
preliminary studies (G.Q.D., R.A.V., and D.B., unpublished
work) suggest that the murine CML target is a pluripotent cell
also. Although the data above do not clearly demonstrate
stem-cell infection, our isolation of Mac-i-positive cell lines
that have rearranged both immunoglobulin ,u alleles suggests
transfer of v-abl to an early cell capable of differentiating
along both myeloid and lymphoid pathways. As we have used
viruses of similar titer under identical infection conditions in
both our bcr-abl and v-abl studies, it seems likely that we are
initially introducing these activated abl genes into similar
populations of cells.
A third potentially important variable in determination of
the phenotype of disease is the nature of the retroviral vector
system used to introduce activated abl variants into marrow
cells. Although the vector used in our v-abl and bcr-abl
experiments is identical, helper virus was in the producer cell
population used in the v-abl experiments but not in the
previous study. This may account, at least in part, for the
frequency of lymphoid disease observed in mice whose
marrow is infected with v-abl. In contrast to the helper-free
system, infection by v-abl of an expanding pool of maturing
pre-B cell progenitors could occur after transplantation of
marrow into the lethally irradiated recipient animals. It is
difficult, however, to see how this could restrict the ability of
v-abl to transform the target-cell population that could give
rise to a CML-like syndrome. One might argue that the
presence of helper virus could accelerate disease onset in
other lineages, such that recipient animals would die of
different malignancies before exhibiting the CML phenotype.
However, the latency of CML-like disease in mice receiving
bcr-abl-infected marrow was sufficiently short that one
would expect to see at least some animals with that disease
if v-abl behaved identically with respect to transformation of
a myeloid progenitor cell population. Yet another argument
against the importance of helper virus comes from the results
ofChung et al. (5), who used a helper-free v-abl producer cell
line. They also observe malignant macrophage-like and lym-
phoid disease but do not document massive expansion of the
mature granulocyte compartment or the presence of provirus
in this lineage in vivo.
If these explanations do not account for the difference in
diseases induced by bcr-abl and v-abl, structural differences
between the two proteins are a potential explanation. Several
structural features determining the transforming properties of
activated c-abl variants have been previously defined. Motifs
necessary for transformation in all cell types include the SH2
region and kinase domains, whereas the presence of a myris-
toylation site near the N terminus of activated proteins
appears required for fibroblast transformation (23, 24). Al-
though deletion of regions such as SH3 can activate trans-
forming ability, the most common naturally occurring muta-
tions involve appending additional sequence information to
the N terminus of a partly deleted gene product. These
include addition of retroviral gag sequences (in A-MuLV or
Hardy Zuckerman feline sarcoma virus) or bcr sequences (in
the Philadelphia translocation) to a partially deleted c-abl
molecule. The role ofthese additions remains poorly defined,
but several mechanisms can be envisioned. Steric hindrance
of the interaction between regulatory regions normally pres-
ent in c-abl and other molecules may occur. The SH3 domain
appears to function as a negative regulator oftransformation,
whereas the SH2 domain recently has been shown to interact
specifically with several proteins that have undergone tyro-
sine phosphorylation in cells transformed by activated abl
variants (25). Another mechanism might involve acquisition
of an additional functionality by the abl protein. gag se-
quences, in part, determine protein stability in lymphoid cells
(26) and subcellular distribution through provision ofa myris-
toylation site (27). Although no enzymatic activity has been
proposed for gag, a serine/threonine kinase activity has
previously been suggested for the bcr gene product (28).
Further investigation of the structural properties of these abl
variants will clearly be necessary to identify regions respon-
sible for the specificity of transformation they exhibit.
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